SF
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
$2.20 +0.00% (+$0.00)
1M +13.99%
Market Cap ¥39.0B
P/E Ratio 7.75x
Div. Yield 2.61%
ROE 10.34%
Bulios Fair Price
$1.3
40.9% downside
Current Price
$2.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SFOSF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
80 /100
Cheap P/FCF 44.06x
P/E 7.75x
P/B 0.80x
Growth
12 /100
Declining Book val. growth 3.01%
EPS growth 4.13%
Rev. growth 2.75%
Profitability
46 /100
Moderate Op. margin 8.30%
Gross margin 50.13%
FCF margin 1.43%
Quality
34 /100
Average ROA 4.01%
ROIC 3.80%
Asset turnover 0.49x
Debt
46 /100
Moderate Int. coverage 2.83x
Debt/Equity 0.81x
Net debt/EBITDA 2.75x
Stability
78 /100
Stable EPS volatility 32.84%
Beta 0.44x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SFOSF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yi Liu
Employees
40,603
Headquarters
Shanghai
Upcoming events
29 MAR
Earnings
Upcoming earnings report